Skip to content
Diazoxide
Proglycem (diazoxide) is a small molecule pharmaceutical. Diazoxide was first approved as Hyperstat on 1982-01-01. It is used to treat hypoglycemia and malignant hypertension in the USA. It is known to target ATP-sensitive inward rectifier potassium channel 8, ATP-sensitive inward rectifier potassium channel 11, and nicotinamide phosphoribosyltransferase.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
nutritional and metabolic diseasesD009750
Trade Name
FDA
EMA
Proglycem (generic drugs available since 2019-12-20, discontinued: Hyperstat)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Diazoxide
Tradename
Company
Number
Date
Products
PROGLYCEMTevaN-017453 RX1982-01-01
1 products, RLD, RS
Show 2 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
diazoxideANDA2023-05-03
proglycemNew Drug Application2020-12-08
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hypoglycemiaHP_0001943D007003E16.2
malignant hypertensionEFO_1001031D006974
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
C02: Antihypertensives
C02D: Arteriolar smooth muscle, agents acting on
C02DA: Thiazide derivatives acting on arteriolar smooth muscle
C02DA01: Diazoxide
V: Various drug classes in atc
V03: All other therapeutic products
V03A: All other therapeutic products
V03AH: Drugs for treatment of hypoglycemia
V03AH01: Diazoxide
HCPCS
Code
Description
J1730
Injection, diazoxide, up to 300 mg
Clinical
Clinical Trials
25 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 1 diabetes mellitusD003922EFO_0001359E10314
Type 2 diabetes mellitusD003924EFO_0001360E11314
Glucose metabolism disordersD044882314
HypoglycemiaD007003HP_0001943E16.21112
Neuroendocrine tumorsD018358EFO_1001901D3A.811
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pregnancy in diabeticsD011254O24.91111
Newborn infant diseasesD007232111
CraniopharyngiomaD00339711
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypertriglyceridemiaD015228EFO_0004211325
ObesityD009765EFO_0001073E66.944
HyperinsulinismD006946HP_0000842E16.1112
DyslipidemiasD050171HP_000311911
Prader-willi syndromeD011218Orphanet_739Q87.1111
DepressionD003863F33.9111
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myocardial stunningD01768211
Prediabetic stateD011236EFO_1001121R73.0311
Insulin resistanceD007333EFO_000261411
Non-alcoholic fatty liver diseaseD065626EFO_0003095K75.8111
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Reperfusion injuryD01542711
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDIAZOXIDE
INNdiazoxide
Description
Diazoxide is a benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies. It has a role as an antihypertensive agent, a sodium channel blocker, a vasodilator agent, a K-ATP channel agonist, a beta-adrenergic agonist, a cardiotonic drug, a bronchodilator agent, a sympathomimetic agent and a diuretic. It is a benzothiadiazine, a sulfone and an organochlorine compound.
Classification
Small molecule
Drug class
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1
Identifiers
PDB4LV9
CAS-ID364-98-7
RxCUI3327
ChEMBL IDCHEMBL181
ChEBI ID4495
PubChem CID3019
DrugBankDB01119
UNII IDO5CB12L4FN (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
KCNJ8
KCNJ8
KCNJ11
KCNJ11
NAMPT
NAMPT
Organism
Homo sapiens
Gene name
KCNJ8
Gene synonyms
NCBI Gene ID
Protein name
ATP-sensitive inward rectifier potassium channel 8
Protein synonyms
Inward rectifier K(+) channel Kir6.1, inwardly rectifying potassium channel KIR6.1, Potassium channel, inwardly rectifying subfamily J member 8, potassium voltage-gated channel subfamily J member 8, uKATP-1
Uniprot ID
Mouse ortholog
Kcnj8 (16523)
ATP-sensitive inward rectifier potassium channel 8 (P97794)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 5,834 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1,472 adverse events reported
View more details